{{vm.title}}
25{{vm.includesText}}
{{item}}
{{vm.selectText}}
{{ vm.welcomeLabel.trim() }},
{{ vm.userName }}
{{ vm.text }}
{{vm.newUser1}} {{vm.newUser2}} {{vm.newUser3}} {{vm.newUser4}}
{{ vm.unknownUser }}
{{ vm.title }}
{{ vm.title }}
{{ vm.title }}
{{$store.state.data.search.serverData.config.placeholder}}
{{ vm.heading }}
{{ vm.closeTabLabel }}
How to compete and win in a world of biosimilars
How to compete and win in a world of biosimilars
A relatively new part of the pharma industry, biosimilars are coming to the U.S.
By Mark Ginestro, Principal, KPMG Strategy and Jason Moore, Manager, KPMG Strategy
This nascent market is poised for huge growth, and no doubt, biosimilars will be a disrupter. The challenge companies need to face now is how they will adapt their commercial strategies to be successful. In this paper, we detail a range of possible commercial approaches, while also addressing the issues of partnering, regulatory developments and go-to-market considerations.
Want to know more?
Download the report (PDF 1.8 MB). And if you want to talk, we’d be happy to hear from you.
